Clinical Trials Logo

Clinical Trial Summary

This is a Phase 2 non-randomized, open-label study to investigate the efficacy, safety and tolerability of RVT-1401 in patients with Warm Autoimmune Hemolytic Anemia.


Clinical Trial Description

This is a Phase 2, non-randomized, sequential, open-label study to investigate the safety, tolerability, PK, PD, and efficacy of RVT-1401 (680 mg/weekly and 340 mg/weekly) in patients with Warm Autoimmune Hemolytic Anemia that is worsening or refractory in spite of therapy with steroids and or immunosuppressants or worsening with steroid or immunosuppressant taper. Two cohorts of participants will be enrolled in a non-randomized sequential approach. Participants will be enrolled into Cohort 1 (680 mg/weekly) first followed by Cohort 2 (340 mg/weekly). Following the initial dose at the Baseline Visit (Week 1, Day 1), study visits will occur weekly throughout the treatment period. Following the final dose at Week 12, visits will occur weekly through Week 14 and then at Week 16 and Week 20. Safety, PK, PD, and clinical assessments will be collected throughout the study. Each participant will participate in the study for up to approximately 24 weeks: up to a 4-week screening period, a 12-week treatment period, and an 8-week follow up period. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04253236
Study type Interventional
Source Immunovant Sciences GmbH
Contact
Status Terminated
Phase Phase 2
Start date August 11, 2020
Completion date April 1, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT05786573 - A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre) Phase 3
Withdrawn NCT03965624 - Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia Phase 2
Recruiting NCT05922839 - Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA Phase 2
Completed NCT01181154 - Rituximab in Auto-Immune Hemolytic Anemia Phase 3
Recruiting NCT05925023 - Sirolimus in the Treatment of Refractory/Relapsed wAIHA Phase 2
Recruiting NCT05757570 - An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias Phase 1/Phase 2
Withdrawn NCT04256148 - ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia Phase 2
Terminated NCT03075878 - A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA) Phase 1/Phase 2
Withdrawn NCT04956276 - Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia Phase 2
Completed NCT03226678 - Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD) Phase 2
Recruiting NCT04119050 - Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia Phase 2/Phase 3
Temporarily not available NCT05221619 - Post-trial Access for Nipocalimab in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)